Intravitreal anti-vascular endothelial growth factor (bevacizumab) in nanophthalmic exudative macular detachment – A new treatment modality

Abstract

Nanophthalmic exudative macular retinal detachment is a known entity, till now the established treatment modality is Scleral Resection. This brief communication suggests a successful new modality of non-surgical, less invasive treatment approach of intravitreal anti-vascular endothelial growth factor in case of exudate macular detachment related to nanophthalmos.